A detailed history of National Bank Of Canada transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, National Bank Of Canada holds 1,351 shares of NBIX stock, worth $169,564. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,351
Previous 737 83.31%
Holding current value
$169,564
Previous $101,000 53.47%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$114.58 - $153.15 $70,352 - $94,034
614 Added 83.31%
1,351 $155,000
Q2 2024

Aug 02, 2024

BUY
$130.86 - $143.19 $1,962 - $2,147
15 Added 2.08%
737 $101,000
Q1 2024

May 13, 2024

SELL
$130.4 - $143.74 $2.9 Million - $3.2 Million
-22,244 Reduced 96.86%
722 $99,000
Q4 2023

Feb 06, 2024

BUY
$106.07 - $132.76 $2.33 Million - $2.92 Million
21,964 Added 2192.02%
22,966 $3.03 Million
Q3 2023

Oct 10, 2023

SELL
$94.02 - $117.1 $4,889 - $6,089
-52 Reduced 4.93%
1,002 $112,000
Q2 2023

Jul 26, 2023

SELL
$89.53 - $104.87 $5.88 Million - $6.89 Million
-65,673 Reduced 98.42%
1,054 $99,000
Q1 2023

Apr 12, 2023

BUY
$94.11 - $123.02 $5.23 Million - $6.84 Million
55,598 Added 499.58%
66,727 $6.75 Million
Q4 2022

Jan 24, 2023

BUY
$106.72 - $127.06 $1.07 Million - $1.27 Million
9,985 Added 872.81%
11,129 $0
Q3 2022

Oct 13, 2022

SELL
$92.03 - $107.81 $13,804 - $16,171
-150 Reduced 11.59%
1,144 $129,000
Q2 2022

Jul 28, 2022

BUY
$75.79 - $100.07 $2,349 - $3,102
31 Added 2.45%
1,294 $126,000
Q1 2022

May 05, 2022

BUY
$72.45 - $94.81 $2,463 - $3,223
34 Added 2.77%
1,263 $118,000
Q4 2021

Jan 24, 2022

BUY
$79.65 - $106.22 $97,889 - $130,544
1,229 New
1,229 $105,000

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.